Baron Ekaterina, Wu Chih Ching, Gupta Kanchan, Wernberg Jessica A, Sheehan Michael T, Sharma Rohit
Surgical Oncology, Marshfield Medical Center, Wisconsin, USA.
Endocrinology, Marshfield Medical Center, Wisconsin, USA.
Cureus. 2024 Mar 17;16(3):e56336. doi: 10.7759/cureus.56336. eCollection 2024 Mar.
Autosomal dominant hereditary paraganglioma-pheochromocytoma syndrome (HPPS) is a rare genetic disorder characterized by neuroendocrine tumor development associated with pathogenic variants in succinate dehydrogenase (SDH) enzyme complex genes. Particularly, HPPS linked to SDHB mutation poses a significant clinical challenge due to its association with aggressive tumor features and a high risk of malignancy. Our report underscores the diversity in the presentation of patients with SDHB-mutated paraganglioma and the feasibility of managing it with a minimally invasive surgical approach. In the first case, a 17-year-old female was diagnosed with a metabolically active, poorly differentiated extra-adrenal retroperitoneal paraganglioma that required challenging robotic resection. Cascade genetic testing revealed an SDHB mutation not only in her but also in three family members, pointing to the inherited nature of the syndrome. Conversely, the second case involves a 37-year-old male with an asymptomatic well-differentiated left paraaortic paraganglioma incidentally found during an unrelated medical examination. Robotic converted-to-open resection allowed the successful removal of the mass. Subsequent germline testing confirmed a deleterious SDHB mutation, initiating a process of familial cascade testing. Both patients remained symptom- and recurrence-free at 12 and six months, respectively. Through these cases, and supported by a literature review, we highlight the variable clinical presentations of HPPS, arising from the same genetic alteration. The successful application of minimally invasive surgical techniques, combined with genetic evaluation, emphasizes the necessity for a comprehensive, tailored approach to treatment and surveillance. This strategy not only addresses the immediate clinical needs but also fosters proactive management of at-risk family members, ensuring a multidisciplinary approach to this complex hereditary condition.
常染色体显性遗传性副神经节瘤 - 嗜铬细胞瘤综合征(HPPS)是一种罕见的遗传性疾病,其特征是神经内分泌肿瘤的发生与琥珀酸脱氢酶(SDH)酶复合物基因的致病性变异有关。特别是,与SDHB突变相关的HPPS由于其与侵袭性肿瘤特征和高恶性风险相关,带来了重大的临床挑战。我们的报告强调了SDHB突变型副神经节瘤患者临床表现的多样性以及采用微创外科手术方法进行治疗的可行性。在第一个病例中,一名17岁女性被诊断患有代谢活跃、低分化的肾上腺外腹膜后副神经节瘤,需要进行具有挑战性的机器人切除术。级联基因检测不仅在她身上发现了SDHB突变,在三名家庭成员中也发现了该突变,表明该综合征具有遗传性。相反,第二个病例涉及一名37岁男性,在一次无关的体检中偶然发现了无症状的高分化左主动脉旁副神经节瘤。机器人辅助转为开放手术成功切除了肿块。随后的胚系检测证实了有害的SDHB突变,启动了家族级联检测过程。两名患者分别在12个月和6个月时均无症状且无复发。通过这些病例,并在文献综述的支持下,我们强调了由相同基因改变引起的HPPS临床表现的多样性。微创外科技术的成功应用与基因评估相结合,强调了采用全面、个性化的治疗和监测方法的必要性。这种策略不仅满足了当前的临床需求,还促进了对有风险家庭成员的积极管理,确保对这种复杂的遗传性疾病采取多学科方法。